Shield Therapeutics plc
Company Profile
Shield is a commercial stage pharmaceutical company focused on the commercialisation of Accrufer®/Feraccru® (ferric maltol), an innovative oral iron therapy for iron deficiency differentiated from other irons by its efficacy, broad label and well-tolerated formulation. The Group has launched Accrufer® in the US with an exclusive, multi-year collaboration agreement with Viatris, Inc. Feraccru® is commercialised in the UK and European Union by Norgine B.V., that also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.
Accrufer®/Feraccru® has patent coverage until the mid-2030s
Accrufer®/Feraccru® are registered trademarks of the Shield Group
Investor Access
The Company will announce its interim results for the six months ended 30 June 2024 on Wednesday 4 September 2024.
Investors can sign up to Investor Meet Company for free and add to meet Shield Therapeutics plc via the following link: https://www.investormeetcompany.com/shield-therapeutics-plc/register-investorWednesday 4 September 2024 at 4:30pm BST
Event | Date |
Year End | 31 December |
Half Year End | 30 June |
Preliminary Results* | May |
Interim Results* | September |
AGM* | June |
* Months based on previous announcements of this kind